Navigation Links
Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME)
Date:12/20/2010

011, VEGF Trap-Eye could provide patients and physicians with a new treatment option for central retinal vein occlusion."

"After reporting positive results from our global Phase 3 program (VIEW 1 and VIEW 2 studies) for the treatment of the neovascular form of age related macular degeneration (wet AMD), we are pleased to also have a positive Phase 3 trial with VEGF Trap-Eye in central retinal vein occlusion, a potential second indication," said Kemal Malik, MD, Head of Global Development and member of the Bayer HealthCare Executive Committee.  "We are working diligently with Regeneron to prepare regulatory filings for VEGF Trap-Eye in wet AMD to submit in the first half of 2011."

Detailed results for COPERNICUS will be presented at the Angiogenesis Conference in Miami, Florida in February 2011.

Regeneron will receive a $10 million milestone payment from Bayer HealthCare in connection with the COPERNICUS trial meeting its primary endpoint and received a $10 million milestone payment in December 2010 for the positive VIEW 1 and VIEW 2 trial results in wet AMD.

Phase 2 DME ResultsRegeneron and Bayer HealthCare also reported 52 week follow-up results from the Phase 2 DA VINCI study in patients with diabetic macular edema (DME).  In this study, the previously reported visual acuity gains achieved with VEGF Trap-Eye treatment over 24 weeks (the primary endpoint of the study) were maintained or numerically improved up to completion of the study at week 52 in all VEGF Trap-Eye study groups, including 2mg dosed every other month. Based on these positive results, Regeneron and Bayer HealthCare are discussing plans to initiate Phase 3 studies.

In this double-masked, prospective, randomized, multi-center Phase 2 trial, entitled DA VINCI (DME And VEGF Trap-Eye: INvestigation of Clinical Impact), 221 patients with clinically significant DME with central macular involvement were random
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. Regeneron Reports Third Quarter 2009 Financial and Operating Results
6. Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
7. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
8. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
9. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
10. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
11. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... May 4, 2015   Synthetic Biologics, Inc. ... on protecting the microbiome, as well as treating other ... appointed Chief Financial Officer, Treasurer and Secretary effective June ... who will be leaving the Company in May to ... Synthetic Biologics operational, financial and international biotech industry experience, ...
(Date:5/4/2015)... BOULDER, Colo., May 4, 2015  Array BioPharma ... for the third quarter of its fiscal year ... Chief Executive Officer of Array, noted, "With the close ... binimetinib and encorafenib, two innovative oncology products in ... each product in 2016. These transformative transactions have ...
(Date:5/4/2015)... , May 4, 2015 ... has granted an Orphan Drug Designation (ODD) for rimeporide, ... dystrophy (DMD). DMD is a rare, life-threatening disease affecting ... muscle loss. It is the most common and serious ... a selective sodium/proton exchanger type-1 inhibitor, originally developed by ...
Breaking Medicine Technology:Steven Shallcross Named Chief Financial Officer of Synthetic Biologics 2Steven Shallcross Named Chief Financial Officer of Synthetic Biologics 3Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 2Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 3Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 4Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 5Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 6Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 7Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 8Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 9Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2015 10EspeRare's Investigational Compound Rimeporide Receives European Orphan Drug Designation in Duchenne Muscular Dystrophy 2
(Date:5/4/2015)... (PRWEB) May 04, 2015 Peacock Alley ... our mothers. He said, “My mother was the most beautiful ... wrap her in lovely, feminine prints and textures ... Look no further than the Eloise Robe to get you ... with its cap sleeve and tapered waist. It is available ...
(Date:5/4/2015)... Today, Cireson reveals the following key ... to strengthen core service & asset management solutions ... consume Microsoft System Center and Cireson via Microsoft Azure ... Company transitioning from a direct sales presence to ... with expanding new solutions for password reset management, gamification, ...
(Date:5/3/2015)... Singapore (PRWEB) May 03, 2015 ... enterprise collaboration across platforms and devices, today announced ... Association of Privacy Professionals (IAPP) Asia Privacy Forum, ... Hotel Orchard. Throughout the event, AvePoint will showcase ... hybrid, and cloud platforms. , Visit AvePoint for ...
(Date:5/3/2015)... Michigan (PRWEB) May 03, 2015 ... on their Facebook page. , Their Facebook ... the many services the Practice has, it’s multiple locations, ... , Women’s Excellence has a very strong social media ... Instagram and You Tube. , Women’s Excellence is ...
(Date:5/3/2015)... 2015 Leading international program provider, ... be awarding the 2015 Harris Wofford Global Service Fellowships. ... are the deserving recipients of the award named after ... Llewellyn Wofford. The two recipients were chosen for their ... health. , CFHI is one of seven organizations ...
Breaking Medicine News(10 mins):Health News:Feminine Classics for Mother's Day Gifts from Peacock Alley 2Health News:Cireson Unveils New Microsoft Cloud & System Center Strategy 2Health News:Cireson Unveils New Microsoft Cloud & System Center Strategy 3Health News:Cireson Unveils New Microsoft Cloud & System Center Strategy 4Health News:AvePoint Showcases Compliance and Data Privacy Solutions as Platinum Sponsor of IAPP Asia Privacy Forum 2015 2Health News:AvePoint Showcases Compliance and Data Privacy Solutions as Platinum Sponsor of IAPP Asia Privacy Forum 2015 3Health News:AvePoint Showcases Compliance and Data Privacy Solutions as Platinum Sponsor of IAPP Asia Privacy Forum 2015 4Health News:SF-based Global Health Non-Profit Awards Harris Wofford Global Service Fellowship 2Health News:SF-based Global Health Non-Profit Awards Harris Wofford Global Service Fellowship 3
... LOS ANGELES, Sept. 1 Azteca America television network is proud ... Gavin Newsom on the Sept. 1 broadcast of "Issues: Caras ... , , As a self-styled "social liberal and ... healthcare and San Francisco is probably the highest profile city in ...
... 21 hours later with milder heart attacks, study shows , ... at hospital emergency rooms with chest pains can wait as ... electrocardiogram (EKG) shows evidence of a heart attack, a new ... key measures of heart damage and one-month death rates in ...
... , , National Veterans ... WASHINGTON, Sept. 1 More than 120 Veterans from across ... writing or visual arts contests are preparing to attend the National Veterans ... , "The Creative Arts Festival represents the top achievements ...
... ... orthopaedic surgeons Dr. James R. Andrews and Dr. Lonnie Paulos now beginning its second ... Gulf ... Sports Medicine is now providing free orthopaedic exams and assessments to high school ...
... , , , ... American Imaging Management(R) (AIM), an operating subsidiary of WellPoint, Inc. (NYSE: ... industry, today commended articles on diagnostic imaging that appear in the August 27, ... , The article "Exposure to Low-Dose Ionizing Radiation from Medical ...
... to detect the disease while it is still treatable ... say they have found small molecules in the blood ... have diagnostic implications in the future. , Levels of ... from pancreatic cancer, the fourth-leading cancer killer in the ...
Cached Medicine News:Health News:San Francisco Mayor Gavin Newsom Talks About Immigration and Drugs on Azteca America's 'Issues: Caras y Voces' 2Health News:Sometimes Angioplasty Can Wait 2Health News:VA Honors Veterans Who Are Artists, Performers 2Health News:Andrews Institute for Orthopaedics and Sports Medicine Now Providing Free Orthopaedic Exams and Assessments on Saturday Mornings to Student Athletes 2Health News:Andrews Institute for Orthopaedics and Sports Medicine Now Providing Free Orthopaedic Exams and Assessments on Saturday Mornings to Student Athletes 3Health News:American Imaging Management Reacts to New England Journal of Medicine Articles on Diagnostic Imaging 2Health News:Blood Test May Spot Pancreatic Cancer Early 2
Gentamicin is a selection antibiotic used for selection of a Bac-to-Bac recombinant expression bacmid following transposition. Gentamicin is provided as a solution at a concentration of 50 mg/ml....
1.0% Tryptone, 0.5% yeast extract, 0.5% Sodium Chloride, 1.5% agarose....
1% tryptone, 0.5% yeast extract, 1.0% Sodium Chloride, 1.5% agar....
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
Medicine Products: